Basic Information
Vafseo
Regulatory Information
EMEA/H/C/005131
April 24, 2023
February 23, 2023
4
March 27, 2025
Company Information
Germany
Medice Arzneimittel Pütter GmbH & Co. KG Kuhloweg 37-39 D-58638 Iserlohn
Medice Arzneimittel Pütter Gmbh & Co. Kg
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
Overview Summary
Vafseo is a medicine used to treat the symptoms of anaemia (low red blood cell counts) caused by chronic kidney disease (long-term, progressive decrease in the ability of the kidneys to work properly) in adult patients on dialysis (a technique for removing unwanted substances and excess fluid from the blood when the kidneys do not work well enough). Vafseo contains the active substance vadadustat.